Veracyte (VCYT) Projected to Post Earnings on Tuesday

Veracyte (NASDAQ:VCYT) will likely be releasing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect Veracyte to post earnings of $0.32 per share and revenue of $124.6180 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Veracyte Price Performance

NASDAQ VCYT opened at $36.08 on Friday. The stock has a market capitalization of $2.84 billion, a PE ratio of 109.34 and a beta of 2.11. Veracyte has a 1 year low of $22.61 and a 1 year high of $47.32. The business’s 50-day moving average is $33.50 and its 200 day moving average is $29.77.

Analyst Upgrades and Downgrades

Several analysts have weighed in on VCYT shares. Zacks Research raised Veracyte from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Veracyte in a research report on Wednesday, October 8th. Canaccord Genuity Group started coverage on Veracyte in a research report on Monday, October 20th. They set a “hold” rating and a $40.00 price objective on the stock. Morgan Stanley set a $28.00 price objective on Veracyte and gave the company an “underweight” rating in a research report on Friday, August 8th. Finally, Wall Street Zen raised Veracyte from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.90.

Insider Transactions at Veracyte

In other news, CEO Marc Stapley sold 7,667 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $30.41, for a total value of $233,153.47. Following the sale, the chief executive officer directly owned 334,185 shares of the company’s stock, valued at $10,162,565.85. The trade was a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Annie Mcguire sold 2,283 shares of the business’s stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $33.69, for a total value of $76,914.27. Following the completion of the sale, the senior vice president directly owned 91,599 shares in the company, valued at approximately $3,085,970.31. This represents a 2.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 18,299 shares of company stock valued at $610,799 in the last ninety days. 1.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Veracyte

A number of hedge funds have recently made changes to their positions in VCYT. Royal Bank of Canada boosted its position in shares of Veracyte by 23.3% in the 1st quarter. Royal Bank of Canada now owns 28,712 shares of the biotechnology company’s stock worth $852,000 after purchasing an additional 5,435 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Veracyte by 12.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 195,793 shares of the biotechnology company’s stock worth $5,805,000 after purchasing an additional 21,330 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Veracyte by 94.7% in the 1st quarter. Jane Street Group LLC now owns 216,909 shares of the biotechnology company’s stock worth $6,431,000 after purchasing an additional 105,499 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Veracyte by 54.1% in the 1st quarter. Intech Investment Management LLC now owns 42,762 shares of the biotechnology company’s stock worth $1,268,000 after purchasing an additional 15,017 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Veracyte by 32.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 48,786 shares of the biotechnology company’s stock worth $1,319,000 after purchasing an additional 11,889 shares in the last quarter.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.